drugset / Trial / NCT06706310
Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study uses random, double -blindness, placebo control, and phase multi -center test design. All subjects who meet the standards receive TQ-A3334 per tablet/placebo nucleoside (acid) analog. A total of 116 subjects are needed.
Timeline
- Start
- 2024-12-04
- Primary completion
- 2025-06-22
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TQ-A3334 | Other / unclassified | 0.2 mg | — |
| Comparator | TQ-A3334 | Other / unclassified | 0.5 mg | — |